Consider buying Intel (INTC) as its strong earnings guidance signals a potential business turnaround. For a high-risk, high-reward opportunity, Sarepta Therapeutics (SRPT) is a speculative buy based on a potential path to FDA re-approval for its key drug. Conversely, a strong bearish conviction is held against the quantum computing sector, viewing it as fundamentally overvalued. This presents a potential short-selling opportunity in stocks like IonQ (IONQ) and D-Wave (QBTS) for investors who believe the sector is a bubble.

Sarepta Therapeutics (SRPT)

• The discussion centers on a potential path for one of Sarepta's drugs to return to the market after facing issues with the FDA.
• The proposed solution is a small safety trial of 10 to 20 patients at a lower dose to assess if liver enzyme elevation is less severe.
• This is viewed as the FDA "cracking the door open a tiny tiny bit" for the drug's re-approval.
• The speaker notes that the drug, a gene therapy for Duchenne muscular dystrophy, has had serious side effects, including liver toxicity and two patient deaths.
• Despite the risks, the speaker expresses a bullish sentiment, stating, "I liked the stock. I bought more earlier."
• He mentions having a significant position, approximately 20% of his portfolio.

Takeaways

• High-Risk, High-Reward Biotech Play: SRPT represents a speculative investment opportunity heavily dependent on a future FDA decision.
• Bull Case: A successful, small-scale safety trial could lead to the drug being re-approved, potentially with a strict warning label (a "black box" warning). This would likely cause the stock price to increase significantly.
• Bear Case / Risk Factors: The primary risk is the drug's known liver toxicity. If the new trial fails or the FDA ultimately denies re-approval, the stock could fall sharply. This is a binary event with a high degree of uncertainty.

Quantum Computing Sector (IONQ, D-Wave)

• The speaker expresses an extremely bearish view on the quantum computing sector.
• He specifically mentions IonQ (IONQ) and D-Wave (QBTS) as examples of what he considers overvalued companies.
• He makes a very strong statement: "Quantum's got to go to zero. I don't care. Quantum's going to zero."
• The speaker's rationale is a belief that the valuations are unjustified, calling it "bullshit" that these companies are worth more than his own.

Takeaways

• Strong Bearish Sentiment: The speaker believes quantum computing stocks are in a bubble and are fundamentally worthless, presenting a potential short-selling opportunity for investors who share this view.
• High-Conviction Thesis: This is not a casual opinion; the speaker is adamant that the sector is destined for failure.
• Risk for Shorts: Investors considering shorting these stocks should be aware of the high risk of a "short squeeze," where the stock price rapidly increases, forcing short-sellers to buy back shares at a loss. The sector is volatile and driven by long-term technological promises.

Intel (INTC)

• The speaker analyzes Intel's earnings guidance in real-time.
• He notes the guidance range is $12.6 billion to $13.6 billion.
• This is seen as positive because the market consensus ("the street") was at the low end of that range, $12.6 billion.
• His immediate reaction is highly bullish, viewing it as a sign of a potential turnaround for the company.
• He exclaims, "wow that's good... that's a big number... buy this shit."
• He acts on this conviction immediately, attempting to buy the stock and ultimately getting a fill at $22.80 per share.
• He adds a note of caution, stating, "I could be interpreting wrong, by the way. I'm not up to date on all semiconductor stocks."

Takeaways

• Bullish on Turnaround: The better-than-expected guidance is interpreted as a key indicator that Intel's business may be recovering.
• Catalyst-Driven Trade: This is an example of trading on a specific news event (earnings guidance). The speaker believes the market has not fully priced in the positive news.
• Acknowledged Risk: While bullish, the speaker admits he is not a deep expert on the semiconductor industry, suggesting investors should do their own research before following suit.